CHNXF (ChitogenX) Moat Score: 0/10 (As of Jul. 10, 2026)


What is ChitogenX Moat Score?

ChitogenX has the Moat Score of 0, which implies that the company might have No Moat - No discernible moat.

ChitogenX has No Moat: ChitogenX Inc has some proprietary technology but lacks market leadership, brand strength, and regulatory barriers. Its competitive advantages are not durable.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes ChitogenX might have No Moat - No discernible moat.

ChitogenX  (OTCPK:CHNXF) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

ChitogenX Moat Score Related Terms

ChitogenX Business Description

Address 16667 Hymus Boulevard, Kirkland, Montreal, QC, CAN, H9H 4R9
ChitogenX Inc is a clinical-stage biotech company. It operates in one segment, which is the development of novel therapeutic soft tissue repair technologies.